Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital

OBJECTIVE: To evaluate the outcomes of acute myeloid leukemia patients who were older than 60 years of age at the time of diagnosis following the implementation of a treatment algorithm based on age, performance status, and cytogenetic results. METHODS: We retrospectively compared the results of 31 elderly acute myeloid leukemia patients (median age of 74 years) who were treated according to the new algorithm. RESULTS: Fifteen patients with a good performance status and no unfavorable karyotypes were treated with either intensive cytotoxic chemotherapy (<70 years, nine cases) or adapted etoposide, 6-thioguanine and idarubicine (&gt;70 years, six cases); 16 cases with a poor performance status or unfavorable cytogenetics received supportive care only. Six patients achieved a complete remission and two achieved a partial remission after chemotherapy. There were three toxic deaths during induction, two in the adapted etoposide, 6-thioguanine and idarubicine group and one in the intensive cytotoxic chemotherapy group. The overall median survival time was 2.96 months, 1.3 months in the supportive care group, and 4.6 months in the treatment group. CONCLUSIONS: Our results illustrate the importance of treatment guidelines adapted to local resources in an attempt to improve the survival of elderly acute myeloid leukemia patients in developing countries.

Saved in:
Bibliographic Details
Main Authors: Sandes,Alex Freire, Ribeiro,Juliana Correa da Costa, Barroso,Rodrigo S., Silva,Maria R.R., Chauffaille,Maria L.L.F.
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322011000800005
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322011000800005
record_format ojs
spelling oai:scielo:S1807-593220110008000052011-08-30Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University HospitalSandes,Alex FreireRibeiro,Juliana Correa da CostaBarroso,Rodrigo S.Silva,Maria R.R.Chauffaille,Maria L.L.F. Acute Myeloid Leukemia Elderly Intensive Chemotherapy Adapted ETI Prognosis OBJECTIVE: To evaluate the outcomes of acute myeloid leukemia patients who were older than 60 years of age at the time of diagnosis following the implementation of a treatment algorithm based on age, performance status, and cytogenetic results. METHODS: We retrospectively compared the results of 31 elderly acute myeloid leukemia patients (median age of 74 years) who were treated according to the new algorithm. RESULTS: Fifteen patients with a good performance status and no unfavorable karyotypes were treated with either intensive cytotoxic chemotherapy (<70 years, nine cases) or adapted etoposide, 6-thioguanine and idarubicine (&gt;70 years, six cases); 16 cases with a poor performance status or unfavorable cytogenetics received supportive care only. Six patients achieved a complete remission and two achieved a partial remission after chemotherapy. There were three toxic deaths during induction, two in the adapted etoposide, 6-thioguanine and idarubicine group and one in the intensive cytotoxic chemotherapy group. The overall median survival time was 2.96 months, 1.3 months in the supportive care group, and 4.6 months in the treatment group. CONCLUSIONS: Our results illustrate the importance of treatment guidelines adapted to local resources in an attempt to improve the survival of elderly acute myeloid leukemia patients in developing countries.info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.66 n.8 20112011-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322011000800005en10.1590/S1807-59322011000800005
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Sandes,Alex Freire
Ribeiro,Juliana Correa da Costa
Barroso,Rodrigo S.
Silva,Maria R.R.
Chauffaille,Maria L.L.F.
spellingShingle Sandes,Alex Freire
Ribeiro,Juliana Correa da Costa
Barroso,Rodrigo S.
Silva,Maria R.R.
Chauffaille,Maria L.L.F.
Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital
author_facet Sandes,Alex Freire
Ribeiro,Juliana Correa da Costa
Barroso,Rodrigo S.
Silva,Maria R.R.
Chauffaille,Maria L.L.F.
author_sort Sandes,Alex Freire
title Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital
title_short Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital
title_full Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital
title_fullStr Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital
title_full_unstemmed Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital
title_sort improving the outcomes of elderly patients with acute myeloid leukemia in a brazilian university hospital
description OBJECTIVE: To evaluate the outcomes of acute myeloid leukemia patients who were older than 60 years of age at the time of diagnosis following the implementation of a treatment algorithm based on age, performance status, and cytogenetic results. METHODS: We retrospectively compared the results of 31 elderly acute myeloid leukemia patients (median age of 74 years) who were treated according to the new algorithm. RESULTS: Fifteen patients with a good performance status and no unfavorable karyotypes were treated with either intensive cytotoxic chemotherapy (<70 years, nine cases) or adapted etoposide, 6-thioguanine and idarubicine (&gt;70 years, six cases); 16 cases with a poor performance status or unfavorable cytogenetics received supportive care only. Six patients achieved a complete remission and two achieved a partial remission after chemotherapy. There were three toxic deaths during induction, two in the adapted etoposide, 6-thioguanine and idarubicine group and one in the intensive cytotoxic chemotherapy group. The overall median survival time was 2.96 months, 1.3 months in the supportive care group, and 4.6 months in the treatment group. CONCLUSIONS: Our results illustrate the importance of treatment guidelines adapted to local resources in an attempt to improve the survival of elderly acute myeloid leukemia patients in developing countries.
publisher Faculdade de Medicina / USP
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322011000800005
work_keys_str_mv AT sandesalexfreire improvingtheoutcomesofelderlypatientswithacutemyeloidleukemiainabrazilianuniversityhospital
AT ribeirojulianacorreadacosta improvingtheoutcomesofelderlypatientswithacutemyeloidleukemiainabrazilianuniversityhospital
AT barrosorodrigos improvingtheoutcomesofelderlypatientswithacutemyeloidleukemiainabrazilianuniversityhospital
AT silvamariarr improvingtheoutcomesofelderlypatientswithacutemyeloidleukemiainabrazilianuniversityhospital
AT chauffaillemariallf improvingtheoutcomesofelderlypatientswithacutemyeloidleukemiainabrazilianuniversityhospital
_version_ 1756432126666866688